4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses

BACKGROUND: Second-generation tyrosine kinase inhibitors(2G-TKI) have increased considerably over the past few years. Despite good and maintained results with imatinib, 2G-TKI have shown a growing trend in their use due to their quick and deep response. However, there is no clear positioning between...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Hosp Pharm
Autori principali: Soto, CM Valencia, López-Sepúlveda, R, Artime-Rodríguez-Hermida, F, Herrera, S Guijarro, Villacañas-Palomares, MV, Gómez, P Nieto, Miguel, S Cortes-de
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Group 2018
Soggetti:
Section 4: Clinical pharmacy services
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535530/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.194
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi